Eos Energy stock falls after Fuzzy Panda issues short report
RADNOR, Pa. - Avantor, Inc. (NYSE:AVTR) introduced a new suite of pre-engineered sterile sampling and PUPSIT (pre-use, post-sterilization integrity testing) assemblies designed to enhance bioprocessing operations, according to a press release statement issued Thursday. The announcement comes as the $7.9 billion market cap company’s stock trades near its 52-week low, having fallen over 25% in the past week. According to InvestingPro analysis, Avantor appears undervalued compared to its fundamentals.
The company’s sterile sampling suite includes four main components: a Needle-Based Sampling System (NBSS) for stainless-steel vessels, a Needle-Free Sampling System (NFSS) for enhanced operator safety, an Exact Volume Sampling System (EVSS) for precise small-volume applications, and OmniTop for flexible chamber options.
The solutions feature modular, multi-sample configurations that reduce contamination risk by minimizing line breaks and operator intervention. Standardized documentation aims to simplify setup and qualification processes.
Avantor’s PUPSIT assemblies incorporate supplier-agnostic components that connect with common filtration trains, designed to help manufacturers maintain closed flow paths during integrity testing after sterilization.
"Biopharmaceutical manufacturers need solutions that are configurable, easy to implement, and consistently perform across scales," said Benoit Gourdier, Executive Vice President of Bioscience Production at Avantor.
The products target both established biologics and emerging advanced therapies, with the company stating the sampling platform is now one of the most comprehensive for bioprocessing applications.
Avantor provides mission-critical products and services to customers in life sciences and advanced technologies industries across 180 countries.
In other recent news, Avantor Inc. has reported its third-quarter earnings for 2025, revealing a slight miss in both earnings per share (EPS) and revenue compared to forecasts. The company reported an EPS of $0.22, which fell short of the anticipated $0.23, and generated $1.62 billion in revenue, missing the forecast of $1.65 billion. Additionally, Avantor experienced a 4.7% decline in organic revenue, which was below the Street’s expectation of a 3.0% decline and the company’s guidance range of -4.0% to -2.0%. Following these results, JPMorgan downgraded Avantor from Overweight to Neutral, reducing the price target to $12.00 from $14.00. BofA Securities also lowered its price target on Avantor to $14.00 from $16.50, citing ongoing pricing challenges impacting the business, though they maintained a Buy rating. These developments reflect investor concerns over missed expectations and strategic challenges facing the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.